Table of Contents PART 01: Executive summary PART 02: Scope of the report PART 03: Research Methodology PART 04: Introduction • Key market highlights PART 05: Understanding of stem cell therapy • History of stem cell research PART 06: Ethical issues and regulatory landscape • Ethical issues of stem cell research at different phases of research PART 07: Key clinical trials • Attractive clinical trial locations to invest • Commercially attractive therapy areas to invest PART 08: Market landscape • Market overview • Five forces analysis PART 09: Market segmentation by therapy • Allogeneic stem cell therapy • Autologous stem cell therapy PART 10: Market segmentation by applications • Dermatology • Musculoskeletal • Cardiovascular PART 11: Geographical segmentation • Stem cell therapy market in Americas • Stem cell therapy market in EMEA • Stem cell therapy market in APAC PART 12: Market drivers • Limitations in traditional organ transplantations fueling the demand for stem cell therapies • Increase in federal funding in stem cell therapy • Growing demand for personalized medicine • Increasing demand to develop effective drugs for cardiology and degenerative disorders PART 13: Impact of drivers PART 14: Market challenges • Stringent regulatory environment affecting the product approvals • Critical ethical challenges with respect to stem cell research • High cost of clinical trials and failure rate in clinical trials PART 15: Impact of drivers and challenges PART 16: Market trends • Evolution of new destinations in the development of stem cell therapies • Increasing inorganic growth strategies such as acquisitions and licensing agreements • Growing focus on the development of drugs for emerging applications • Increasing investments from private enterprises likely to fuel market growth PART 17: Vendor landscape • Competitive scenario PART 18: Key vendor analysis • Holostem Advanced Therapies • JCR Pharmaceuticals • Organogenesis • Osiris Therapeutics • Vericel1 • Other prominent vendors4 PART 19: Appendix7 • List of abbreviations7 PART 20: Explore Technavio9   List of Exhibits Exhibit 01: Developments in stem cell research Exhibit 02: Ethical issues faced by various institutes at different phases of cell therapy research Exhibit 03: Stem cell research policies in Americas Exhibit 04: Stem cell research policies in EMEA Exhibit 05: Stem cell research policies in APAC Exhibit 06: Historical trend of pipeline candidates in different phases Exhibit 07: Snapshot of pipeline trends in stem cell therapy market Exhibit 08: Pipeline landscape by therapeutic area 2016 Exhibit 09: Pipeline by development phase 2016 Exhibit 10: Pipeline snapshot in key therapy areas Exhibit 11: Brief overview of attractive clinical trial locations, therapy areas, and cell types Exhibit 12: Key clinical trials Exhibit 13: Global stem cell therapy market snapshot Exhibit 14: Key marketed products and their company Exhibit 15: Key vendors with robust Phase III pipeline Exhibit 16: Global stem cell therapy market 2016-2021 ($ millions) Exhibit 17: Opportunity analysis in global stem cell therapy market Exhibit 18: Five forces analysis Exhibit 19: Global stem cell therapy market segmentation by therapy 2016 Exhibit 20: Global allogeneic stem cell therapy market 2016-2021 ($ millions) Exhibit 21: Opportunity analysis of allogeneic stem cell therapy market Exhibit 22: Global autologous stem cell therapy market 2016-2021 ($ millions) Exhibit 23: Opportunity analysis of autologous stem cell therapy market Exhibit 24: Global stem cell therapy market segmentation by application 2016 Exhibit 25: Overview of dermatology in stem cell therapy market Exhibit 26: Overview of musculoskeletal in regenerative medicine market Exhibit 27: Overview of cardiovascular in stem cell therapy market Exhibit 28: Segmentation of global stem cell therapy market based on geography 2016 and 2021 Exhibit 29: Stem cell therapy market revenue by geography 2016-2021 ($ millions) Exhibit 30: Market scenario in Americas Exhibit 31: Stem cell therapy market in Americas ($ millions) Exhibit 32: Market scenario in EMEA Exhibit 33: Stem cell therapy market in EMEA ($ millions) Exhibit 34: Market scenario in APAC Exhibit 35: Stem cell therapy market in APAC ($ millions) Exhibit 36: Key stem cell therapy market developments in Japan by global vendors 2015 Exhibit 37: NIH: YoY and growth rate of spending toward stem cell research ($ billions) Exhibit 38: Breakdown of CIRM funding in various stem cell research funding in 2014 ($ billions) Exhibit 39: Active programs under CIRM 2014 Exhibit 40: Details of EC funding Exhibit 41: Impact of drivers Exhibit 42: Impact of drivers and challenges Exhibit 43: Regulatory guidelines in Japan Exhibit 44: Key inorganic growth strategies in global stem cell therapy market Exhibit 45: Competitive structure analysis of global stem cell therapy market 2016 Exhibit 46: Competitive analysis of global stem cell therapy market Exhibit 47: Some of the key approvals in global stem cell therapy Exhibit 48: Strategic success factors of companies in global stem cell therapy market Exhibit 49: Holostem Advanced Therapies: Key highlights Exhibit 50: Holostem Advanced Therapies: Strength assessment Exhibit 51: Holostem Advanced Therapies: Strategy assessment Exhibit 52: Holostem Advanced Therapies: Opportunity assessment Exhibit 53: JCR Pharmaceuticals: Strength assessment Exhibit 54: JCR Pharmaceuticals: Strategy assessment Exhibit 55: JCR Pharmaceuticals: Opportunity assessment Exhibit 56: Organogenesis: Key highlights Exhibit 57: Organogenesis: Strength assessment Exhibit 58: Organogenesis: Strategy assessment Exhibit 59: Organogenesis: Opportunity assessment Exhibit 60: Osiris Therapeutics: Key highlights Exhibit 61: Osiris Therapeutics: Strength assessment Exhibit 62: Osiris Therapeutics: Strategy assessment Exhibit 63: Osiris Therapeutics: Opportunity assessment Exhibit 64: Vericel: Key highlights Exhibit 65: Vericel: Strength assessment Exhibit 66: Vericel: Strategy assessment Exhibit 67: Vericel: Opportunity assessment

Holostem Advanced Therapies, JCR Pharmaceuticals, Organogenesis, Osiris Therapeutics, Vericel, AbbVie, American CryoStem, AM-Pharma, Anterogen, apceth Biopharma, Astellas Pharma, Athersys, Baxter International, Beike Biotechnology, BIOTIME, bluebird bio, Bristol-Myers Squibb, BrainStorm Cell Therapeutics, Brainxell, Caladrius Biosciences, Cellular Biomedicine Group, Cellular Dynamics International (a subsidiary of Fujifilm), Cesca Therapeutics, CHA Biotech, Chugai Pharmaceutical, Citospin, Corestem, Cytori Therapeutics, Daiichi Sankyo, Fujifilm, Gamida Cell, Global Stem Cells Group, Grupo Ferrer Internacional, GlaxoSmithKline, Hemostemix, Histocell, International Stem Cell, Ivy Institute of Stem Cells, Japan Regenerative Medicine, Kangstem Biotech, Kiadis Pharma, Laboratorios Salvat, MEDIPOST, Mesoblast, Nuo Therapeutics, Opsis Therapeutics, Osiris Therapeutics, Pharmicell, Pluristem Therapeutics, Promethera Biosciences, Q Therapeutics, ReNeuron, RHEACELL, Salus Medical Solutions, Sangamo Therapeutics, Shire, Steminent Biotherapeutics, Sumitomo Dainippon Pharma, Taiwan Bio Therapeutics, Takeda Pharmaceutical, Teva Pharmaceutical Industries, Thoratec Corporation, TiGenix, Translational Biosciences, TWO CELLS, U.S. Stem Cell, ViaCyte, VistaGen Therapeutics.